A major 2026 trend in the biotherapeutics sector is the intense competition fueled by the "Patent Cliff" of original blockbuster biologics. In 2026, the market is identifying "Recombinant Cell Lines" as a critical value-shifter for the Biotherapeutics Cell Line Development Market, as dozens of companies race to create highly efficient clones for biosimilar production. This 2026 movement is...